Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusion
Open Access
- 1 April 1994
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 4 (3) , 180-187
- https://doi.org/10.1046/j.1525-1438.1994.04030180.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)Gynecologic Oncology, 1993
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Treatment results - gynecological cancer the “annual report”International Journal of Gynecology & Obstetrics, 1991
- Improved prognosis of ovarian cancer in The Netherlands during the period 1975–1985: A registry-based studyGynecologic Oncology, 1991
- Prognostic factors in advanced epithelial ovarian cancerBritish Journal of Cancer, 1990
- The treatment of advanced ovarian carcinoma (I): Clinical variables associated with prognosisGynecologic Oncology, 1988
- A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinomaGynecologic Oncology, 1987
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Radiation therapy in stage II ovarian carcinoma. The influence of histologic gradeCancer, 1980
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972